Relacorilant Boosts Chemo Sensitivity in Platinum-Resistant Cancers | Medscape

The Food and Drug Administration has approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for adults with platinum-resistant ovarian cancer, a significant step forward for patients whose disease has stopped responding to initial chemotherapy. This marks the first approval of a glucocorticoid receptor antagonist for use in ovarian cancer treatment, offering a new approach to enhance the effectiveness of existing therapies.

Understanding Platinum-Resistant Ovarian Cancer

Ovarian cancer is often diagnosed at a late stage, making treatment challenging. Initial treatment typically involves surgery followed by platinum-based chemotherapy. However, many patients initially respond to this treatment, but the cancer eventually returns, becoming “platinum-resistant.” This resistance means the cancer no longer responds to platinum-based drugs, leaving limited treatment options. According to the National Cancer Institute, ovarian cancer accounts for about 3% of all cancers in women in the United States. https://www.cancer.gov/types/ovarian

How Relacorilant Works: Targeting the Glucocorticoid Receptor

Relacorilant is a glucocorticoid receptor (GR) antagonist. Glucocorticoids are hormones naturally produced by the body, but cancer cells can likewise hijack the GR pathway to promote their own growth and survival, and to resist chemotherapy. Relacorilant blocks the GR, essentially disrupting this protective mechanism within the cancer cells. By blocking the GR, relacorilant aims to re-sensitize the cancer cells to the effects of nab-paclitaxel, a commonly used chemotherapy drug.

ROSELLA Trial: Evidence Supporting the Approval

The approval is based on the Phase 3 ROSELLA trial, which evaluated the safety and efficacy of relacorilant plus nab-paclitaxel chemotherapy. https://www.targetedonc.com/view/fda-approves-relacorilant-for-platinum-resistant-ovarian-cancer The trial successfully met its primary endpoint, demonstrating improved overall survival in patients treated with the combination therapy. The trial results, as reported by Corcept Therapeutics, suggest that adding relacorilant to nab-paclitaxel could become a new standard of care. https://ir.corcept.com/news-releases/news-release-details/overall-survival-primary-endpoint-met-corcepts-pivotal-phase-3/

While the trial demonstrated a statistically significant improvement in overall survival, it’s important to understand the limitations inherent in clinical trials. Factors such as patient selection, trial duration, and the specific chemotherapy regimen used can all influence the results. Further research is needed to determine the long-term effects of relacorilant and to identify which patients are most likely to benefit from this treatment.

What This Means for Patients

For patients with platinum-resistant ovarian cancer, this approval offers a new treatment option when other therapies have failed. The combination of relacorilant and nab-paclitaxel provides a potential pathway to extend survival and improve quality of life. However, it’s crucial to remember that this treatment is not a cure, and individual responses will vary. Patients should discuss the potential benefits and risks of relacorilant with their oncologist to determine if it’s the right choice for them.

Safety Considerations and Side Effects

Relacorilant, like all medications, can cause side effects. Common side effects observed in the ROSELLA trial included fatigue, nausea, and hypertension. The prescribing information includes warnings about adrenal insufficiency, a condition where the adrenal glands don’t produce enough hormones. Patients taking relacorilant will need to be monitored for adrenal insufficiency and may require steroid replacement therapy. https://www.oncologynewscentral.com/drugs/info/fda-approves-relacorilant-combination-for-platinum-resistant-ovarian-cancer

The Role of the Glucocorticoid Receptor in Cancer: A Broader Perspective

The approval of relacorilant highlights the growing understanding of the role of the glucocorticoid receptor in cancer development and treatment resistance. Researchers are increasingly exploring the potential of GR antagonists as a therapeutic strategy in other cancers as well. The success of relacorilant in ovarian cancer may pave the way for similar approaches in other malignancies where the GR pathway is implicated.

What Comes Next: Ongoing Research and Surveillance

The FDA approval is not the end of the story. Ongoing research will focus on further refining the use of relacorilant in ovarian cancer and exploring its potential in other cancer types. Post-marketing surveillance will also be crucial to monitor the long-term safety and effectiveness of the drug in a broader patient population. Researchers will continue to investigate biomarkers that can predict which patients are most likely to respond to relacorilant, allowing for a more personalized approach to treatment. The National Cancer Institute continues to fund research into novel therapies for ovarian cancer, including studies focused on overcoming treatment resistance.